Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
The closing price of Repare Therapeutics Inc (NASDAQ: RPTX) was $2.53 for the day, down -1.17% from the previous closing price of $2.56. In other words, the price has decreased by -$1.17 from its previous closing price. On the day, 3.1 million shares were traded. RPTX stock price reached its highest trading level at $2.56 during the session, while it also had its lowest trading level at $2.525.
Ratios:
Our analysis of RPTX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 10.71 and its Current Ratio is at 10.71. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In the most recent recommendation for the company, Stifel on June 09, 2023, Upgraded its rating to Buy and sets its target price to $16 from $11 previously.
On February 03, 2023, Morgan Stanley Downgraded its rating to Equal-Weight which previously was Overweight and also lowered its target price recommendation from $28 to $15.
On January 06, 2023, CapitalOne started tracking the stock assigning a Overweight rating and target price of $28.CapitalOne initiated its Overweight rating on January 06, 2023, with a $28 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 12 ’25 when Koehler Maria sold 3,596 shares for $1.14 per share. The transaction valued at 4,099 led to the insider holds 227,813 shares of the business.
Zinda Michael sold 5,611 shares of RPTX for $6,397 on Mar 12 ’25. The EVP, CHIEF SCIENTIFIC OFFICER now owns 80,297 shares after completing the transaction at $1.14 per share. On Mar 12 ’25, another insider, Forte Steve, who serves as the EVP, CHIEF FINANCIAL OFFICER of the company, sold 6,884 shares for $1.14 each. As a result, the insider received 7,848 and left with 54,786 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RPTX now has a Market Capitalization of 109064152 and an Enterprise Value of -3508039. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.19 while its Price-to-Book (P/B) ratio in mrq is 0.94. Its current Enterprise Value per Revenue stands at -0.296 whereas that against EBITDA is 0.046.
Stock Price History:
The Beta on a monthly basis for RPTX is 0.99, which has changed by 0.8550725 over the last 52 weeks, in comparison to a change of 0.1877265 over the same period for the S&P500. Over the past 52 weeks, RPTX has reached a high of $2.66, while it has fallen to a 52-week low of $0.89. The 50-Day Moving Average of the stock is 18.90%, while the 200-Day Moving Average is calculated to be 53.28%.
Shares Statistics:
RPTX traded an average of 913.84K shares per day over the past three months and 2290420 shares per day over the past ten days. A total of 42.99M shares are outstanding, with a floating share count of 34.63M. Insiders hold about 19.67% of the company’s shares, while institutions hold 37.15% stake in the company. Shares short for RPTX as of 1765756800 were 352361 with a Short Ratio of 0.39, compared to 1763078400 on 533637. Therefore, it implies a Short% of Shares Outstanding of 352361 and a Short% of Float of 1.2999999.
Earnings Estimates
Repare Therapeutics Inc (RPTX) is currently under the scrutiny of 1.0 analysts, each contributing to the ongoing evaluation of its stock.
Analysts are recommending an EPS of between -$2.11 and -$2.11 for the fiscal current year, implying an average EPS of -$2.11.
Revenue Estimates
A total of 2 analysts have provided revenue estimates for RPTX’s current fiscal year. The highest revenue estimate was $15M, while the lowest revenue estimate was $300k, resulting in an average revenue estimate of $7.65M. In the same quarter a year ago, actual revenue was $53.48M
